Johnson & Johnson (JNJ)
JNJ Gets EU Nod for Imaavy in Generalized Myasthenia Gravis
J&J gains EU approval for Imaavy, the first FcRn blocker for adults and adolescents with generalized myasthenia gravis.
3 Stocks to Buy and Hold: the Long-Term Play for Your Portfolio
Intuitive Surgical shows why now is a good time to consider buying surgical-robot competitor Medtronic. Eli Lilly helps explain why down-and-out drugmaker Pfizer could be worth a close look for long-term investors.
JNJ's Oncology Momentum Builds as It Chases $50B Goal by 2030
JNJ's oncology sales surge on strong drug launches and pipeline momentum, raising the stakes for its ambitious $50B 2030 goal.
Johnson & Johnson (JNJ) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
J&J Up Around 17% in 3 Months: Should You Buy, Sell or Hold the Stock?
J&J's 16.7% rise reflects stronger sales guidance, rapid pipeline advances and improving MedTech momentum amid a recovering sector.
JNJ Stock vs. PFE Stock: Which Pharmaceutical Giant Is A Better Buy?
The pharmaceutical powerhouse Johnson & Johnson (NYSE: JNJ) has significantly outperformed its competitor Pfizer (NYSE: PFE) this year. JNJ's stock has risen by almost 45%, whereas PFE has declined by 6%, greatly exceeding the S&P 500's 13% increase.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
J&J Joins Pharma M&A Bandwagon, to Buy Cancer Biotech for $3.05B
J&J's $3.05B move for Halda adds targeted oral cancer therapies and expands its prostate cancer pipeline amid rising pharma M&A.
Johnson & Johnson (JNJ) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
Johnson & Johnson ( JNJ ) 7th Annual Wolfe Research Healthcare Conference November 17, 2025 10:40 AM EST Company Participants Candice Long - Worldwide Vice President of Immunology David Lee - Global Therapeutic Area Head, Immunology for Janssen Pharmaceutical Conference Call Participants Alexandria Hammond - Wolfe Research, LLC Presentation Alexandria Hammond Wolfe Research, LLC Good morning, everybody. My name is Alex Hammond, and I'm the biopharma analyst here at Wolfe.
Johnson & Johnson strengthens oncology portfolio with $3B Halda Therapeutics acquisition
Johnson & Johnson (NYSE:JNJ) announced that it has entered into a definitive agreement to acquire Halda Therapeutics, a clinical-stage biotechnology company focused on developing targeted oral therapies for solid tumors, for $3.05 billion in cash. Halda's lead candidate, HLD-0915, is a once-daily oral therapy for prostate cancer that received FDA fast track designation in August 2025 following positive preliminary data from Phase 1/2 trials.
Johnson & Johnson to Buy Halda Therapeutics For $3.05 Billion
Johnson & Johnson has agreed to buy clinical-stage biotechnology company Halda Therapeutics for $3.05 billion in cash in a deal that bolsters the healthcare giant's oncology pipeline.
J&J to buy cancer therapy developer Halda Therapeutics for $3.05 billion
Johnson & Johnson said on Monday it would buy Halda Therapeutics for $3.05 billion in cash, expanding its presence in solid tumors and prostate cancer treatments.
